{"gene":"SOCS5","run_date":"2026-06-10T07:46:37","timeline":{"discoveries":[{"year":2002,"finding":"SOCS5 protein interacts with the cytoplasmic region of the IL-4Rα chain irrespective of receptor tyrosine phosphorylation, and this interaction reduces the association of JAK1 with the IL-4 receptor, resulting in inhibition of IL-4-mediated STAT6 activation and suppression of Th2 differentiation.","method":"Co-immunoprecipitation, transgenic mouse overexpression, Th2 differentiation assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP identifying IL-4Rα as binding partner, transgenic mouse model with defined cellular phenotype (reduced Th2 development), replicated across functional readouts","pmids":["12242343"],"is_preprint":false},{"year":2005,"finding":"SOCS5 associates with the EGF receptor complex in an EGF-independent manner and inhibits EGF-driven mitogenic signaling; deletion of the SOCS5 SOCS box abolishes this inhibition, suggesting the mechanism involves SOCS box-mediated recruitment of E3 ubiquitin ligase activity leading to enhanced proteasomal degradation of the EGF-R.","method":"Co-immunoprecipitation, cell proliferation assay with SOCS5 mutants (SOCS box deletion), engineered EGF-responsive cell lines","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Moderate — Co-IP demonstrating EGFR association, domain deletion mutagenesis revealing SOCS box requirement, functional readout in cell proliferation assay, single lab but multiple orthogonal methods","pmids":["15695332"],"is_preprint":false},{"year":2004,"finding":"Socs5-deficient mice generated by targeted gene disruption show no abnormalities in lymphocyte compartment, no deviations in antigen- or cytokine-induced B and T cell proliferation, and no defects in Th1/Th2 differentiation or resistance to Leishmania major infection, indicating SOCS5 is dispensable for regulation of lymphocyte function under these conditions.","method":"Targeted gene disruption (knockout mouse), lymphocyte proliferation assays, Th1/Th2 differentiation assays, Leishmania infection model","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic KO with multiple defined cellular phenotype readouts; contradicts PMID 12242343 on Th1/Th2 role but is a rigorous null finding","pmids":["15199163"],"is_preprint":false},{"year":2013,"finding":"SOCS5 contains a conserved JAK interaction region (JIR) in its N-terminus that mediates direct binding to the JAK kinase domain; co-expression of SOCS5 specifically reduces JAK1 and JAK2 (but not JAK3 or TYK2) autophosphorylation via a mechanism requiring both the JIR and additional N-terminal sequences; SOCS5 can directly inhibit JAK1 kinase activity through a mechanism distinct from SOCS1/SOCS3; additionally, the SOCS5 SH2 domain binds phosphoTyr317 of the adaptor protein Shc-1 with high affinity.","method":"Co-expression autophosphorylation assays, in vitro kinase assays, domain deletion and mutagenesis, SH2 domain binding assays","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vitro kinase activity assay, domain mutagenesis, SH2 binding assay identifying Shc-1 pY317 as substrate; multiple orthogonal methods in single lab","pmids":["23990909"],"is_preprint":false},{"year":2015,"finding":"NMR structural characterization of the JAK interaction region (JIR) within the intrinsically disordered N-terminus of SOCS5 reveals preformed structural elements including an α-helix (residues 224–233) preceded by a turn and extended structure; a phosphorylation site (Ser211) within the JIR was identified and site-directed mutagenesis showed phosphorylation modulates JAK binding.","method":"NMR (chemical shift analysis, relaxation measurements, NOE analysis), site-directed mutagenesis","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR structural characterization with functional validation via mutagenesis; single lab but multiple orthogonal NMR methods plus mutagenesis","pmids":["26173083"],"is_preprint":false},{"year":2017,"finding":"SOCS5 restricts influenza A virus replication in airway epithelium through regulation of EGFR signaling; Socs5-deficient mice exhibit heightened disease severity with increased viral titres; restoration of SOCS5 levels in primary COPD epithelial cells (which have reduced SOCS5) restricted influenza infection.","method":"Socs5 knockout mice, viral titration, restoration experiments in primary epithelial cells, weight loss measurements","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO mouse with defined phenotypic readout (viral titres, weight loss), plus restoration experiment in primary cells; multiple orthogonal approaches in one study","pmids":["28195529"],"is_preprint":false},{"year":2016,"finding":"In CLL patients, elevated SOCS5 (induced via IL-10-driven STAT3 activation) inhibits STAT6 activation downstream of IL-4Rα, thereby impairing differentiation of functionally mature dendritic cells; IL-10 treatment of healthy donor monocytes mimics this effect through STAT3-dependent SOCS5 upregulation.","method":"Western blot for signaling molecules, monocyte-derived DC differentiation assay, IL-10 treatment, flow cytometry for DC surface markers and cytokine secretion","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined signaling pathway placement using patient-derived cells and pharmacological mimicry; single lab, two complementary approaches","pmids":["27317770"],"is_preprint":false},{"year":2014,"finding":"MeCP2 promotes expression of miR-124, which represses translation of SOCS5 mRNA; loss of MeCP2 leads to SOCS5 accumulation, which in turn inhibits cytokine-dependent activation of STAT1 and STAT3, impairing Th1 and Th17 cell differentiation.","method":"MeCP2 knockdown/knockout in CD4+ T cells, miR-124 expression analysis, Western blot for SOCS5 and phospho-STAT1/STAT3, Th1/Th17 differentiation assays","journal":"Science signaling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic loss-of-function with defined mechanistic pathway (MeCP2→miR-124→SOCS5→STAT signaling), single lab, multiple orthogonal readouts","pmids":["24619648"],"is_preprint":false},{"year":2016,"finding":"JEV infection downregulates miR-432 in human brain microglial cells, causing upregulation of SOCS5; elevated SOCS5 suppresses STAT1 phosphorylation and ISRE activity, thereby dampening antiviral JAK-STAT signaling and promoting JEV replication; SOCS5 knockdown restored STAT1 phosphorylation and suppressed viral replication.","method":"3'UTR luciferase reporter assay validating miR-432 targeting of SOCS5, miR-432 mimic/SOCS5 siRNA knockdown, Western blot for phospho-STAT1, ISRE reporter assay, viral replication assay","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — luciferase reporter confirming direct targeting, functional rescue experiments with defined signaling readouts; single lab","pmids":["27282499"],"is_preprint":false},{"year":2019,"finding":"SOCS5 promotes HCC cell migration and invasion by inactivating PI3K/Akt/mTOR-mediated autophagy; dual inhibition of SOCS5 and mTOR further enhances autophagy and anti-metastatic effects; stable knockdown of SOCS5 reduces HCC cell metastasis in vivo.","method":"SOCS5 siRNA knockdown and overexpression, PI3K/Akt/mTOR pathway Western blot, autophagy assays, in vitro migration/invasion assays, in vivo metastasis model","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss- and gain-of-function with defined pathway readouts, in vivo validation; single lab","pmids":["31406106"],"is_preprint":false},{"year":2018,"finding":"SOCS5 acts as a tumor suppressor in liver cancer by regulating TSC1 and downstream mTOR signaling; miR-18a and miR-25 directly target SOCS5 to promote HCC tumorigenesis.","method":"miRNA target validation (luciferase reporter), SOCS5 overexpression/knockdown in HCC cell lines, Western blot for TSC1 and mTOR pathway components, cell proliferation assays","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — luciferase reporter confirming direct miRNA targeting of SOCS5, pathway analysis via Western blot; single lab, multiple assays","pmids":["30191950"],"is_preprint":false},{"year":2019,"finding":"SOCS5 expression in T-ALL is epigenetically silenced by DNMT3A-mediated DNA methylation and MeCP2-mediated histone deacetylation; SOCS5 silencing activates JAK-STAT signaling and accelerates T-ALL engraftment and leukemia progression in a xenograft model; SOCS5 negatively regulates IL-7 and IL-4 receptor signaling in T-ALL cells.","method":"DNMT3A/MeCP2 inhibition, SOCS5 overexpression/knockdown, Western blot for JAK-STAT pathway, cell cycle analysis, human T-ALL murine xenograft model","journal":"Cancer science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epigenetic mechanism identified with pharmacological and genetic approaches, in vivo xenograft validation; single lab","pmids":["30974024"],"is_preprint":false},{"year":2024,"finding":"SOCS5 interacts with RBMX via its SH2 domain (critical residues Y413 and D443 binding the RBMX RRM domain); the SOCS5-RBMX complex co-stimulates the SREBP1 promoter to induce de novo lipogenesis, promoting HCC metastasis; SH2 domain mutations Y413 and D443 abolish RBMX binding and reverse lipogenesis induction.","method":"Co-IP and GST-pulldown identifying SOCS5-RBMX interaction, SH2 domain point mutagenesis (Y413, D443), SREBP1 promoter assay, proteomics, metabolomics, in vitro and in vivo experiments","journal":"NPJ precision oncology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — reciprocal Co-IP and GST-pulldown, mutagenesis identifying critical binding residues, functional promoter assay and metabolomics; multiple orthogonal methods in single study","pmids":["38429411"],"is_preprint":false},{"year":2007,"finding":"PMA treatment of rat brain astrocytes induces SOCS5 protein expression via activation of Stat3 (tyrosine-phosphorylated Stat3 binds SOCS promoter elements), identifying Stat3-driven transcriptional induction as a mechanism for SOCS5 upregulation.","method":"Western blot for SOCS5 protein, phospho-Stat3 detection, gel-shift (EMSA) assay showing Stat3 binding to SOCS promoter elements","journal":"Molecules and cells","confidence":"Medium","confidence_rationale":"Tier 2–3 / Weak — EMSA showing nuclear Stat3 binding to SOCS promoter elements, Western blot for SOCS5 induction; single lab, limited mechanistic dissection of SOCS5 specifically","pmids":["17464217"],"is_preprint":false},{"year":2022,"finding":"SOCS5 knockdown inhibits HCC cell invasion and migration by suppressing HIF-1α expression, preventing HIF-1α-dependent mitochondrial damage; this effect operates through the PI3K/Akt/mTOR/HIF-1α signaling axis as confirmed by rescue experiments with PI3K and mTOR inhibitors.","method":"SOCS5 siRNA knockdown, CoCl2 hypoxia model, immunofluorescence, electron microscopy, PI3K/mTOR inhibitor rescue experiments, in vivo metastasis and xenograft models","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological rescue with pathway inhibitors placing SOCS5 upstream of PI3K/Akt/mTOR/HIF-1α; single lab, multiple orthogonal assays","pmids":["36319626"],"is_preprint":false},{"year":2022,"finding":"SOCS5 contributes to TMZ resistance in glioblastoma by enhancing Bcl-2 transcription, which promotes autophagy; knockdown of SOCS5 inhibits TMZ chemoresistance through inhibition of Bcl-2-mediated autophagy, and upregulation of Bcl-2 reverses this effect.","method":"SOCS5 knockdown/overexpression, Western blot for Bcl-2, autophagy assays, TMZ resistance assays, rescue experiments with Bcl-2 overexpression","journal":"Bioengineered","confidence":"Low","confidence_rationale":"Tier 3 / Weak — mechanistic claim (SOCS5 enhances Bcl-2 transcription) based on Western blot and rescue experiments in single lab without direct transcription assay for SOCS5 on Bcl-2 promoter","pmids":["35730472"],"is_preprint":false},{"year":2023,"finding":"POU2F1 acts as an upstream transcriptional activator of SOCS5, and elevated SOCS5 promotes diabetic retinopathy progression by upregulating CDKN1A (p21), driving cell cycle arrest and cellular senescence; SOCS5 knockdown mitigated retinal tissue damage, vascular leakage, and DNA damage in DR models.","method":"siRNA silencing of POU2F1 and SOCS5, Western blot for CDKN1A, in vitro (HG-induced HRMECs) and in vivo (STZ-induced DR mouse) models, apoptosis and senescence assays","journal":"Cell death discovery","confidence":"Low","confidence_rationale":"Tier 3 / Weak — pathway placement via siRNA knockdown and Western blot; single lab, no direct transcriptional binding assay for POU2F1 on SOCS5 promoter reported in abstract","pmids":["41922309"],"is_preprint":false},{"year":2000,"finding":"CIS6/SOCS5 was cloned as a human homologue with structural features (SH2 domain and SOCS box) consistent with the SOCS family of negative regulators of JAK signaling; its gene was mapped to human chromosome bands 2p21 and 3p22.","method":"cDNA cloning, Northern blot for tissue expression, fluorescence in situ hybridization for chromosomal mapping","journal":"Cytogenetics and cell genetics","confidence":"Low","confidence_rationale":"Tier 3 / Weak — cloning and chromosomal mapping; function inferred from structural homology, no direct functional assay","pmids":["10773671"],"is_preprint":false}],"current_model":"SOCS5 is an intracellular suppressor of cytokine and growth factor signaling that operates through at least two distinct mechanisms: (1) its conserved N-terminal JAK interaction region (JIR) directly binds and inhibits JAK1 and JAK2 kinase activity, while its SH2 domain engages phosphoTyr317 of Shc-1 to dampen EGF/growth factor signaling; (2) it binds the IL-4Rα cytoplasmic domain independently of receptor phosphorylation to block STAT6 activation; its SOCS box recruits E3 ubiquitin ligase activity to promote proteasomal degradation of the EGF receptor; and it interacts via its SH2 domain (residues Y413/D443) with the RBMX RRM domain to co-activate SREBP1-driven lipogenesis in HCC; SOCS5 expression is itself regulated by STAT3-driven transcription, miR-124-mediated translational repression, and DNMT3A/MeCP2-mediated epigenetic silencing, placing it as a feedback node in the JAK-STAT pathway with additional roles in EGFR, PI3K/Akt/mTOR, and HIF-1α signaling."},"narrative":{"mechanistic_narrative":"SOCS5 is an intracellular negative regulator of cytokine and growth-factor signaling that acts on the JAK-STAT and EGFR pathways through multiple, structurally distinct interaction modules [PMID:23990909, PMID:15695332]. Its conserved N-terminal JAK interaction region (JIR), an intrinsically disordered segment containing a preformed α-helix (residues 224–233) whose JAK binding is modulated by Ser211 phosphorylation, directly binds the JAK kinase domain and selectively suppresses JAK1 and JAK2 (but not JAK3 or TYK2) autophosphorylation by a mechanism distinct from SOCS1/SOCS3; its SH2 domain additionally engages phosphoTyr317 of the adaptor Shc-1 [PMID:23990909, PMID:26173083]. SOCS5 also binds the IL-4Rα cytoplasmic tail independently of receptor phosphorylation, displacing JAK1 from the receptor and inhibiting IL-4-driven STAT6 activation [PMID:12242343], and associates with the EGF receptor complex EGF-independently to inhibit mitogenic signaling, an effect that requires the SOCS box and is consistent with SOCS box-mediated recruitment of E3 ubiquitin ligase activity promoting EGFR degradation [PMID:15695332]. Through this control of EGFR signaling SOCS5 restricts influenza A virus replication in airway epithelium, where its loss heightens disease severity and viral titres [PMID:28195529]. SOCS5 is positioned as an inducible feedback node: it is transcriptionally upregulated by tyrosine-phosphorylated STAT3 binding SOCS promoter elements [PMID:17464217, PMID:27317770], translationally repressed by miR-124 (downstream of MeCP2) and other miRNAs [PMID:24619648], and epigenetically silenced by DNMT3A/MeCP2 in T-ALL, where silencing reactivates JAK-STAT signaling and accelerates leukemia progression [PMID:30974024]. In hepatocellular carcinoma SOCS5 acquires oncogenic, signaling-independent functions: its SH2 domain (critical residues Y413/D443) binds the RBMX RRM domain, and the SOCS5-RBMX complex co-activates the SREBP1 promoter to drive de novo lipogenesis and metastasis [PMID:38429411], while SOCS5 also promotes HCC migration and invasion via PI3K/Akt/mTOR-mediated autophagy and a downstream HIF-1α axis [PMID:31406106, PMID:36319626]. A Socs5 knockout shows the protein is dispensable for lymphocyte development and Th1/Th2 differentiation under standard conditions [PMID:15199163].","teleology":[{"year":2000,"claim":"Established SOCS5 as a candidate negative regulator of JAK signaling by cloning it and recognizing the SH2-domain/SOCS-box architecture that defines the SOCS family.","evidence":"cDNA cloning, Northern blot, and FISH chromosomal mapping","pmids":["10773671"],"confidence":"Low","gaps":["Function inferred from structural homology with no direct functional assay","No binding partner or substrate identified","Dual chromosomal mapping (2p21 and 3p22) unresolved"]},{"year":2002,"claim":"Provided the first mechanism, showing SOCS5 binds the IL-4Rα cytoplasmic tail independent of receptor phosphorylation to displace JAK1 and block STAT6, dampening Th2 differentiation.","evidence":"Co-IP, transgenic mouse overexpression, and Th2 differentiation assays","pmids":["12242343"],"confidence":"High","gaps":["Phosphorylation-independent binding interface on IL-4Rα not mapped","Th2 role contradicted by later knockout data","Did not establish whether endogenous SOCS5 levels recapitulate the overexpression phenotype"]},{"year":2004,"claim":"Tested SOCS5 necessity genetically and found it dispensable for lymphocyte function and Th1/Th2 differentiation, narrowing where SOCS5 is physiologically required.","evidence":"Targeted gene-disruption knockout mouse with lymphocyte proliferation, Th1/Th2, and Leishmania infection readouts","pmids":["15199163"],"confidence":"High","gaps":["Possible redundancy with other SOCS proteins not excluded","Conditions tested may not engage SOCS5-dependent contexts","Conflicts with the overexpression-based Th2 phenotype"]},{"year":2005,"claim":"Extended SOCS5 action to growth-factor signaling by showing EGF-independent association with the EGFR complex and SOCS-box-dependent inhibition of mitogenic signaling.","evidence":"Co-IP, SOCS-box deletion mutants, and proliferation assays in engineered EGF-responsive lines","pmids":["15695332"],"confidence":"High","gaps":["E3 ligase recruitment and EGFR ubiquitination inferred but not directly demonstrated","Specific EGFR residues or adaptor mediating binding not defined"]},{"year":2013,"claim":"Defined the direct enzymatic mechanism, identifying the N-terminal JIR that binds the JAK kinase domain and selectively inhibits JAK1/JAK2 activity, plus an SH2-Shc-1 pY317 interaction.","evidence":"Co-expression autophosphorylation assays, in vitro kinase assays, domain mutagenesis, and SH2 binding assays","pmids":["23990909"],"confidence":"High","gaps":["Structural basis of JAK1/JAK2 selectivity over JAK3/TYK2 unresolved","Functional consequence of Shc-1 pY317 binding in cells not established"]},{"year":2015,"claim":"Resolved the conformational basis of JAK recognition, showing the disordered JIR contains a preformed α-helix and a Ser211 phosphosite that tunes JAK binding.","evidence":"NMR chemical shift, relaxation, and NOE analysis with site-directed mutagenesis","pmids":["26173083"],"confidence":"High","gaps":["Kinase responsible for Ser211 phosphorylation unknown","No co-structure of the JIR bound to JAK"]},{"year":2007,"claim":"Identified an upstream input, showing PMA-induced STAT3 binds SOCS promoter elements to drive SOCS5 transcription, placing SOCS5 in a feedback loop.","evidence":"Western blot for SOCS5, phospho-Stat3 detection, and EMSA in rat astrocytes","pmids":["17464217"],"confidence":"Medium","gaps":["EMSA used generic SOCS promoter elements rather than dissecting the SOCS5 promoter specifically","Direct STAT3 occupancy of the SOCS5 locus not shown"]},{"year":2014,"claim":"Established post-transcriptional and epigenetic control, showing the MeCP2→miR-124 axis represses SOCS5 translation, with SOCS5 accumulation inhibiting STAT1/STAT3 and Th1/Th17 differentiation.","evidence":"MeCP2 knockdown/knockout in CD4+ T cells, miR-124 analysis, and Th1/Th17 differentiation assays","pmids":["24619648"],"confidence":"Medium","gaps":["Direct miR-124 binding to the SOCS5 3'UTR not separately validated here","Mechanism of SOCS5-mediated STAT1/STAT3 inhibition in this context not dissected"]},{"year":2016,"claim":"Linked SOCS5 regulation to immune dysfunction, showing IL-10/STAT3-driven SOCS5 upregulation blocks STAT6 and impairs dendritic cell maturation in CLL, and miR-432 loss raises SOCS5 to suppress STAT1 antiviral signaling during JEV infection.","evidence":"Patient-derived cells with IL-10 mimicry and DC differentiation assays (CLL); 3'UTR luciferase reporter, siRNA rescue, and ISRE/viral replication assays (JEV)","pmids":["27317770","27282499"],"confidence":"Medium","gaps":["Whether SOCS5-mediated STAT inhibition uses JAK displacement or kinase inhibition in these settings not resolved","Direct SOCS5 occupancy of receptors in patient cells not shown"]},{"year":2017,"claim":"Demonstrated a physiological antiviral role, showing SOCS5 restricts influenza A in airway epithelium via EGFR regulation, with loss worsening disease and restoration protecting COPD epithelium.","evidence":"Socs5 knockout mice, viral titration, weight loss, and restoration in primary epithelial cells","pmids":["28195529"],"confidence":"High","gaps":["Molecular link between SOCS5-EGFR control and viral restriction not fully detailed","Relevance of JAK-inhibitory function to this phenotype not separated from EGFR function"]},{"year":2018,"claim":"Assigned SOCS5 a tumor-suppressor role in liver cancer through TSC1/mTOR regulation, with miR-18a and miR-25 directly targeting SOCS5 to drive HCC.","evidence":"miRNA luciferase target validation, SOCS5 gain/loss-of-function, and TSC1/mTOR Western blots","pmids":["30191950"],"confidence":"Medium","gaps":["Conflicts with reports of oncogenic SOCS5 function in HCC","Mechanistic link between SOCS5 and TSC1 not biochemically defined"]},{"year":2019,"claim":"Revealed context-dependent oncogenic activity, showing SOCS5 promotes HCC migration/invasion via PI3K/Akt/mTOR-mediated autophagy, and that DNMT3A/MeCP2-driven SOCS5 silencing accelerates T-ALL by reactivating JAK-STAT.","evidence":"SOCS5 knockdown/overexpression with pathway Western blots and in vivo metastasis (HCC); epigenetic inhibition and xenograft (T-ALL)","pmids":["31406106","30974024"],"confidence":"Medium","gaps":["Opposing tumor-suppressor vs oncogenic roles of SOCS5 in HCC unreconciled","Direct molecular target linking SOCS5 to PI3K/Akt/mTOR not identified"]},{"year":2022,"claim":"Expanded the HCC oncogenic mechanism through a HIF-1α axis and proposed a glioblastoma chemoresistance role via Bcl-2-mediated autophagy.","evidence":"SOCS5 knockdown with PI3K/mTOR inhibitor rescue and metastasis models (HCC); SOCS5 knockdown/overexpression with Bcl-2 rescue (GBM)","pmids":["36319626","35730472"],"confidence":"Medium","gaps":["Bcl-2 transcriptional enhancement by SOCS5 lacks a direct promoter assay","How a SOCS-family signaling inhibitor mechanistically activates oncogenic axes remains undefined"]},{"year":2024,"claim":"Defined a non-canonical SOCS5 function, showing its SH2 domain (Y413/D443) binds the RBMX RRM domain and the complex co-activates the SREBP1 promoter to drive lipogenesis and HCC metastasis.","evidence":"Co-IP, GST-pulldown, SH2 point mutagenesis, SREBP1 promoter assay, proteomics, and metabolomics","pmids":["38429411"],"confidence":"High","gaps":["How the SOCS5-RBMX complex engages the SREBP1 promoter mechanistically not resolved","Relationship of this nuclear/lipogenic role to SOCS5's cytoplasmic signaling-inhibitory functions unclear"]},{"year":null,"claim":"How SOCS5 switches between its canonical signaling-suppressor role (JAK inhibition, IL-4Rα/EGFR regulation) and its context-dependent oncogenic functions (RBMX/SREBP1 lipogenesis, PI3K/mTOR/HIF-1α) remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of full-length SOCS5 bound to JAK or EGFR","E3 ligase identity and direct ubiquitination substrates not confirmed","Opposing tumor-suppressor and oncogenic roles, especially in HCC, not reconciled"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[3]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,1,3]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[3,12]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,1,3]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,3]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,5,11]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[1]}],"complexes":[],"partners":["IL4R","EGFR","JAK1","JAK2","SHC1","RBMX"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O75159","full_name":"Suppressor of cytokine signaling 5","aliases":["Cytokine-inducible SH2 protein 6","CIS-6","Cytokine-inducible SH2-containing protein 5"],"length_aa":536,"mass_kda":61.2,"function":"SOCS family proteins form part of a classical negative feedback system that regulates cytokine signal transduction. May be a substrate-recognition component of a SCF-like ECS (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Inhibits for instance EGF signaling by mediating the degradation of the EGF receptor/EGFR. Involved in the regulation of T-helper cell differentiation by inhibiting of the IL4 signaling pathway which promotes differentiation into the Th2 phenotype. Can also partially inhibit IL6 and LIF signaling","subcellular_location":"","url":"https://www.uniprot.org/uniprotkb/O75159/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SOCS5","classification":"Not Classified","n_dependent_lines":93,"n_total_lines":1208,"dependency_fraction":0.07698675496688742},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SOCS5","total_profiled":1310},"omim":[{"mim_id":"616337","title":"SUPPRESSOR OF CYTOKINE SIGNALING 4; SOCS4","url":"https://www.omim.org/entry/616337"},{"mim_id":"607094","title":"SUPPRESSOR OF CYTOKINE SIGNALING 5; SOCS5","url":"https://www.omim.org/entry/607094"},{"mim_id":"131550","title":"EPIDERMAL GROWTH FACTOR RECEPTOR; EGFR","url":"https://www.omim.org/entry/131550"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Cytosol","reliability":"Approved"},{"location":"Nucleoplasm","reliability":"Additional"},{"location":"Plasma membrane","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/SOCS5"},"hgnc":{"alias_symbol":["KIAA0671","SOCS-5","CIS6","CISH6","Cish5"],"prev_symbol":[]},"alphafold":{"accession":"O75159","domains":[{"cath_id":"-","chopping":"275-288_357-371_481-530","consensus_level":"medium","plddt":82.9501,"start":275,"end":530},{"cath_id":"3.30.505.10","chopping":"381-477","consensus_level":"medium","plddt":93.7957,"start":381,"end":477}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O75159","model_url":"https://alphafold.ebi.ac.uk/files/AF-O75159-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O75159-F1-predicted_aligned_error_v6.png","plddt_mean":61.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SOCS5","jax_strain_url":"https://www.jax.org/strain/search?query=SOCS5"},"sequence":{"accession":"O75159","fasta_url":"https://rest.uniprot.org/uniprotkb/O75159.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O75159/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O75159"}},"corpus_meta":[{"pmid":"12242343","id":"PMC_12242343","title":"Expression of the suppressor of cytokine signaling-5 (SOCS5) negatively regulates IL-4-dependent STAT6 activation and Th2 differentiation.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12242343","citation_count":171,"is_preprint":false},{"pmid":"31406106","id":"PMC_31406106","title":"SOCS5 inhibition induces autophagy to impair metastasis in hepatocellular carcinoma cells via the PI3K/Akt/mTOR pathway.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/31406106","citation_count":111,"is_preprint":false},{"pmid":"16210657","id":"PMC_16210657","title":"The control of allergic conjunctivitis by suppressor of cytokine signaling (SOCS)3 and SOCS5 in a murine model.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16210657","citation_count":90,"is_preprint":false},{"pmid":"15695332","id":"PMC_15695332","title":"Suppressor of cytokine signaling (SOCS)-5 is a potential negative regulator of epidermal growth factor signaling.","date":"2005","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15695332","citation_count":79,"is_preprint":false},{"pmid":"28195529","id":"PMC_28195529","title":"Suppressor of cytokine signaling (SOCS)5 ameliorates influenza infection via inhibition of EGFR signaling.","date":"2017","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/28195529","citation_count":65,"is_preprint":false},{"pmid":"27282499","id":"PMC_27282499","title":"Japanese Encephalitis Virus exploits the microRNA-432 to regulate the expression of Suppressor of Cytokine Signaling (SOCS) 5.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27282499","citation_count":64,"is_preprint":false},{"pmid":"15199163","id":"PMC_15199163","title":"SOCS5 is expressed in primary B and T lymphoid cells but is dispensable for lymphocyte production and function.","date":"2004","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15199163","citation_count":58,"is_preprint":false},{"pmid":"31233116","id":"PMC_31233116","title":"MicroRNA-301a promotes pancreatic cancer invasion and metastasis through the JAK/STAT3 signaling pathway by targeting SOCS5.","date":"2020","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/31233116","citation_count":53,"is_preprint":false},{"pmid":"24619648","id":"PMC_24619648","title":"MeCP2 reinforces STAT3 signaling and the generation of effector CD4+ T cells by promoting miR-124-mediated suppression of SOCS5.","date":"2014","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/24619648","citation_count":53,"is_preprint":false},{"pmid":"31539118","id":"PMC_31539118","title":"MiR-9-5p could promote angiogenesis and radiosensitivity in cervical cancer by targeting SOCS5.","date":"2019","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31539118","citation_count":51,"is_preprint":false},{"pmid":"31473323","id":"PMC_31473323","title":"LncRNA FER1L4 induces apoptosis and suppresses EMT and the activation of PI3K/AKT pathway in osteosarcoma cells via inhibiting miR-18a-5p to promote SOCS5.","date":"2019","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/31473323","citation_count":50,"is_preprint":false},{"pmid":"30191950","id":"PMC_30191950","title":"A novel SOCS5/miR-18/miR-25 axis promotes tumorigenesis in liver cancer.","date":"2018","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30191950","citation_count":46,"is_preprint":false},{"pmid":"31411118","id":"PMC_31411118","title":"MiR-151a-3p Promotes Postmenopausal Osteoporosis by Targeting SOCS5 and Activating JAK2/STAT3 Signaling.","date":"2019","source":"Rejuvenation research","url":"https://pubmed.ncbi.nlm.nih.gov/31411118","citation_count":40,"is_preprint":false},{"pmid":"23990909","id":"PMC_23990909","title":"Suppressor of Cytokine Signaling (SOCS) 5 utilises distinct domains for regulation of JAK1 and interaction with the adaptor protein Shc-1.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23990909","citation_count":37,"is_preprint":false},{"pmid":"30414568","id":"PMC_30414568","title":"Angpt2 Induces Mesangial Cell Apoptosis through the MicroRNA-33-5p-SOCS5 Loop in Diabetic Nephropathy.","date":"2018","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/30414568","citation_count":34,"is_preprint":false},{"pmid":"27317770","id":"PMC_27317770","title":"Deregulation of SOCS5 suppresses dendritic cell function in chronic lymphocytic leukemia.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27317770","citation_count":32,"is_preprint":false},{"pmid":"32155348","id":"PMC_32155348","title":"lncRNA HAND2-AS1 Inhibits Liver Cancer Cell Proliferation and Migration by Upregulating SOCS5 to Inactivate the JAK-STAT Pathway.","date":"2020","source":"Cancer biotherapy & radiopharmaceuticals","url":"https://pubmed.ncbi.nlm.nih.gov/32155348","citation_count":31,"is_preprint":false},{"pmid":"30790683","id":"PMC_30790683","title":"BRM transcriptionally regulates miR-302a-3p to target SOCS5/STAT3 signaling axis to potentiate pancreatic cancer metastasis.","date":"2019","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/30790683","citation_count":30,"is_preprint":false},{"pmid":"30974024","id":"PMC_30974024","title":"Epigenetic silencing of SOCS5 potentiates JAK-STAT signaling and progression of T-cell acute lymphoblastic leukemia.","date":"2019","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/30974024","citation_count":29,"is_preprint":false},{"pmid":"22081311","id":"PMC_22081311","title":"SOCS5 and SOCS6 have similar expression patterns in normal and cancer tissues.","date":"2011","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22081311","citation_count":28,"is_preprint":false},{"pmid":"31200002","id":"PMC_31200002","title":"Long noncoding RNA TUSC7 inhibits cell proliferation, migration and invasion by regulating SOCS4 (SOCS5) expression through targeting miR-616 in endometrial carcinoma.","date":"2019","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31200002","citation_count":25,"is_preprint":false},{"pmid":"34666613","id":"PMC_34666613","title":"LncRNA DHRS4-AS1 ameliorates hepatocellular carcinoma by suppressing proliferation and promoting apoptosis via miR-522-3p/SOCS5 axis.","date":"2021","source":"Bioengineered","url":"https://pubmed.ncbi.nlm.nih.gov/34666613","citation_count":25,"is_preprint":false},{"pmid":"30292646","id":"PMC_30292646","title":"Upregulation of miR-132 contributes to the pathophysiology of COPD via targeting SOCS5.","date":"2018","source":"Experimental and molecular pathology","url":"https://pubmed.ncbi.nlm.nih.gov/30292646","citation_count":24,"is_preprint":false},{"pmid":"33935775","id":"PMC_33935775","title":"Leonurine-Repressed miR-18a-5p/SOCS5/JAK2/STAT3 Axis Activity Disrupts CML malignancy.","date":"2021","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33935775","citation_count":21,"is_preprint":false},{"pmid":"32844573","id":"PMC_32844573","title":"Long non-coding RNA HCG11 sponging miR-522-3p inhibits the tumorigenesis of non-small cell lung cancer by upregulating SOCS5.","date":"2020","source":"Thoracic cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32844573","citation_count":19,"is_preprint":false},{"pmid":"36333771","id":"PMC_36333771","title":"Stellate ganglion block relieves acute lung injury induced by severe acute pancreatitis via the miR-155-5p/SOCS5/JAK2/STAT3 axis.","date":"2022","source":"European journal of medical research","url":"https://pubmed.ncbi.nlm.nih.gov/36333771","citation_count":19,"is_preprint":false},{"pmid":"32894543","id":"PMC_32894543","title":"LncRNA CASC2 inhibits cell proliferation, metastasis and EMT through miR-18a/SOCS5 axis in cholangiocarcinoma.","date":"2020","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32894543","citation_count":17,"is_preprint":false},{"pmid":"36471418","id":"PMC_36471418","title":"Mycoplasma gallisepticum escapes the host immune response via gga-miR-365-3p/SOCS5/STATs axis.","date":"2022","source":"Veterinary research","url":"https://pubmed.ncbi.nlm.nih.gov/36471418","citation_count":17,"is_preprint":false},{"pmid":"32224127","id":"PMC_32224127","title":"Long noncoding RNA HAND2-AS1 reduced the viability of hepatocellular carcinoma via targeting microRNA-300/SOCS5 axis.","date":"2020","source":"Hepatobiliary & pancreatic diseases international : HBPD INT","url":"https://pubmed.ncbi.nlm.nih.gov/32224127","citation_count":17,"is_preprint":false},{"pmid":"26173083","id":"PMC_26173083","title":"Structure and Functional Characterization of the Conserved JAK Interaction Region in the Intrinsically Disordered N-Terminus of SOCS5.","date":"2015","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26173083","citation_count":17,"is_preprint":false},{"pmid":"31861450","id":"PMC_31861450","title":"miR-26a Inhibits Feline Herpesvirus 1 Replication by Targeting SOCS5 and Promoting Type I Interferon Signaling.","date":"2019","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/31861450","citation_count":16,"is_preprint":false},{"pmid":"32279214","id":"PMC_32279214","title":"LINC00668 Modulates SOCS5 Expression Through Competitively Sponging miR-518c-3p to Facilitate Glioma Cell Proliferation.","date":"2020","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/32279214","citation_count":13,"is_preprint":false},{"pmid":"35334414","id":"PMC_35334414","title":"Circular RNA circ_0047744 suppresses the metastasis of pancreatic ductal adenocarcinoma by regulating the miR-21/SOCS5 axis.","date":"2022","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/35334414","citation_count":13,"is_preprint":false},{"pmid":"31641102","id":"PMC_31641102","title":"Correction: SOCS5 inhibition induces autophagy to impair metastasis in hepatocellular carcinoma cells via the PI3K/Akt/mTOR pathway.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/31641102","citation_count":13,"is_preprint":false},{"pmid":"35730472","id":"PMC_35730472","title":"SOCS5 contributes to temozolomide resistance in glioblastoma by regulating Bcl-2-mediated autophagy.","date":"2022","source":"Bioengineered","url":"https://pubmed.ncbi.nlm.nih.gov/35730472","citation_count":12,"is_preprint":false},{"pmid":"34059683","id":"PMC_34059683","title":"The LINC01119-SOCS5 axis as a critical theranostic in triple-negative breast cancer.","date":"2021","source":"NPJ breast cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34059683","citation_count":12,"is_preprint":false},{"pmid":"15725575","id":"PMC_15725575","title":"SOCS5 mRNA levels in peripheral blood mononuclear cells (PBMC): a potential bio-marker for monitoring response of uveitis patients to Daclizumab therapy.","date":"2005","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/15725575","citation_count":12,"is_preprint":false},{"pmid":"34856542","id":"PMC_34856542","title":"Salidroside Attenuates Airway Inflammation and Remodeling via the miR-323-3p/SOCS5 Axis in Asthmatic Mice.","date":"2021","source":"International archives of allergy and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34856542","citation_count":11,"is_preprint":false},{"pmid":"17464217","id":"PMC_17464217","title":"PMA activates Stat3 in the Jak/Stat pathway and induces SOCS5 in rat brain astrocytes.","date":"2007","source":"Molecules and cells","url":"https://pubmed.ncbi.nlm.nih.gov/17464217","citation_count":11,"is_preprint":false},{"pmid":"30884777","id":"PMC_30884777","title":"Molecular Cloning and Expression Analysis of Three Suppressors of Cytokine Signaling Genes (SOCS5, SOCS6, SOCS7) in the Mealworm Beetle Tenebrio molitor.","date":"2019","source":"Insects","url":"https://pubmed.ncbi.nlm.nih.gov/30884777","citation_count":10,"is_preprint":false},{"pmid":"32456815","id":"PMC_32456815","title":"miR-101 inhibits feline herpesvirus 1 replication by targeting cellular suppressor of cytokine signaling 5 (SOCS5).","date":"2020","source":"Veterinary microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/32456815","citation_count":10,"is_preprint":false},{"pmid":"38429411","id":"PMC_38429411","title":"SOCS5-RBMX stimulates SREBP1-mediated lipogenesis to promote metastasis in steatotic HCC with HBV-related cirrhosis.","date":"2024","source":"NPJ precision oncology","url":"https://pubmed.ncbi.nlm.nih.gov/38429411","citation_count":9,"is_preprint":false},{"pmid":"31905601","id":"PMC_31905601","title":"Differential Transcription of SOCS5 and SOCS7 in Multiple Sclerosis Patients Treated with Interferon Beta or Glatiramer Acetate.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31905601","citation_count":9,"is_preprint":false},{"pmid":"22252769","id":"PMC_22252769","title":"SOCS3 and SOCS5 mRNA expressions may predict initial steroid response in nephrotic syndrome children.","date":"2011","source":"Folia histochemica et cytobiologica","url":"https://pubmed.ncbi.nlm.nih.gov/22252769","citation_count":9,"is_preprint":false},{"pmid":"37828534","id":"PMC_37828534","title":"Sequential inspiratory muscle exercise-noninvasive positive pressure ventilation alleviates oxidative stress in COPD by mediating SOCS5/JAK2/STAT3 pathway.","date":"2023","source":"BMC pulmonary medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37828534","citation_count":9,"is_preprint":false},{"pmid":"10773671","id":"PMC_10773671","title":"Cloning and expression of CIS6, chromosome assignment to 3p22 and 2p21 by in situ hybridization.","date":"2000","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10773671","citation_count":8,"is_preprint":false},{"pmid":"37646261","id":"PMC_37646261","title":"Resistin stimulates PC-3 prostate cancer cell growth through stimulation of SOCS3 and SOCS5 genes.","date":"2023","source":"Experimental biology and medicine (Maywood, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/37646261","citation_count":8,"is_preprint":false},{"pmid":"32211804","id":"PMC_32211804","title":"miR-802 participates in the inflammatory process of inflammatory bowel disease by suppressing SOCS5.","date":"2020","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/32211804","citation_count":8,"is_preprint":false},{"pmid":"36319626","id":"PMC_36319626","title":"SOCS5 knockdown suppresses metastasis of hepatocellular carcinoma by ameliorating HIF-1α-dependent mitochondrial damage.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/36319626","citation_count":7,"is_preprint":false},{"pmid":"36794154","id":"PMC_36794154","title":"Adenovirus-IL-10 relieves chronic rejection after mouse heart transplantation by inhibiting miR-155 and activating SOCS5.","date":"2023","source":"International journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36794154","citation_count":7,"is_preprint":false},{"pmid":"15825834","id":"PMC_15825834","title":"Milk fat synthesis is unaffected by abomasal infusion of the conjugated diene 18:3 isomers cis-6,trans-10, cis-12 and cis-6,trans-8,cis-12.","date":"2005","source":"Lipids","url":"https://pubmed.ncbi.nlm.nih.gov/15825834","citation_count":7,"is_preprint":false},{"pmid":"36037621","id":"PMC_36037621","title":"SP1/miR-92a-1-5p/SOCS5: A novel regulatory axis in feline panleukopenia virus replication.","date":"2022","source":"Veterinary microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/36037621","citation_count":5,"is_preprint":false},{"pmid":"38267898","id":"PMC_38267898","title":"SOCS5, targeted by miR-155-5p, plays a negative regulatory role in pulmonary hypertension through inhibiting JAK2/STAT3 signaling pathway.","date":"2024","source":"BMC pulmonary medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38267898","citation_count":5,"is_preprint":false},{"pmid":"36384170","id":"PMC_36384170","title":"miR-155-1 as a positive factor for novel duck reovirus replication by regulating SOCS5-mediated interferons.","date":"2022","source":"Virus research","url":"https://pubmed.ncbi.nlm.nih.gov/36384170","citation_count":4,"is_preprint":false},{"pmid":"37358466","id":"PMC_37358466","title":"Reduced NR2F2 Expression in the Host Response to Infectious Bursal Disease Virus Infection Suppressed Viral Replication by Enhancing Type I Interferon Expression by Targeting SOCS5.","date":"2023","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/37358466","citation_count":3,"is_preprint":false},{"pmid":"35117765","id":"PMC_35117765","title":"The overexpression of miRNA-212-5p inhibited the malignant proliferation of liver cancer cells HepG2 and the tumor formation in nude mice with transplanted tumor through down-regulating SOCS5.","date":"2020","source":"Translational cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/35117765","citation_count":3,"is_preprint":false},{"pmid":"37672963","id":"PMC_37672963","title":"Evaluation of SOCS5 mRNA and its association with serum IL-12 levels and rs41379147 SNP in various subsets of allergic disorders: A case control study.","date":"2023","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37672963","citation_count":2,"is_preprint":false},{"pmid":"31094455","id":"PMC_31094455","title":"Association of SOCS5 gene polymorphism with allergic bronchial asthma.","date":"2019","source":"Terapevticheskii arkhiv","url":"https://pubmed.ncbi.nlm.nih.gov/31094455","citation_count":2,"is_preprint":false},{"pmid":"28378729","id":"PMC_28378729","title":"[Role of negative regulators of SOCS1, SOCS3, and SOCS5 gene transcription in the negative cell signaling regulation system in asthma].","date":"2017","source":"Terapevticheskii arkhiv","url":"https://pubmed.ncbi.nlm.nih.gov/28378729","citation_count":2,"is_preprint":false},{"pmid":"33660836","id":"PMC_33660836","title":"Author Correction: LncRNA CASC2 inhibits cell proliferation, metastasis and EMT through miR-18a/SOCS5 axis in cholangiocarcinoma.","date":"2021","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33660836","citation_count":2,"is_preprint":false},{"pmid":"36315981","id":"PMC_36315981","title":"Circ_0031027 adjusts the advancement of cervical cancer by miR-587/SOCS5 axis.","date":"2022","source":"American journal of reproductive immunology (New York, N.Y. : 1989)","url":"https://pubmed.ncbi.nlm.nih.gov/36315981","citation_count":1,"is_preprint":false},{"pmid":"41385946","id":"PMC_41385946","title":"Psoralen promotes SOCS5 to inhibit JAK/STAT3 to alleviate cartilage degeneration in knee osteoarthritis.","date":"2025","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/41385946","citation_count":0,"is_preprint":false},{"pmid":"41922309","id":"PMC_41922309","title":"Mechanistic insights into SOCS5-related DNA damage and cellular senescence in diabetic retinopathy.","date":"2026","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/41922309","citation_count":0,"is_preprint":false},{"pmid":"41843192","id":"PMC_41843192","title":"Morinda officinalis polysaccharide improves osteoporosis by enhancing m⁶A-modified SOCS5 mRNA stability via regulating the hsa_circ_0001165/IGF2BP2 axis.","date":"2026","source":"Molecular genetics and genomics : MGG","url":"https://pubmed.ncbi.nlm.nih.gov/41843192","citation_count":0,"is_preprint":false},{"pmid":"24340963","id":"PMC_24340963","title":"[Association of polymorphism Rs6737848 in the Socs5 gene with bronchial asthma].","date":"2013","source":"Vestnik Rossiiskoi akademii meditsinskikh nauk","url":"https://pubmed.ncbi.nlm.nih.gov/24340963","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":35204,"output_tokens":4932,"usd":0.089796,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":13119,"output_tokens":5133,"usd":0.09696,"stage2_stop_reason":"end_turn"},"total_usd":0.186756,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"SOCS5 protein interacts with the cytoplasmic region of the IL-4Rα chain irrespective of receptor tyrosine phosphorylation, and this interaction reduces the association of JAK1 with the IL-4 receptor, resulting in inhibition of IL-4-mediated STAT6 activation and suppression of Th2 differentiation.\",\n      \"method\": \"Co-immunoprecipitation, transgenic mouse overexpression, Th2 differentiation assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP identifying IL-4Rα as binding partner, transgenic mouse model with defined cellular phenotype (reduced Th2 development), replicated across functional readouts\",\n      \"pmids\": [\"12242343\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"SOCS5 associates with the EGF receptor complex in an EGF-independent manner and inhibits EGF-driven mitogenic signaling; deletion of the SOCS5 SOCS box abolishes this inhibition, suggesting the mechanism involves SOCS box-mediated recruitment of E3 ubiquitin ligase activity leading to enhanced proteasomal degradation of the EGF-R.\",\n      \"method\": \"Co-immunoprecipitation, cell proliferation assay with SOCS5 mutants (SOCS box deletion), engineered EGF-responsive cell lines\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP demonstrating EGFR association, domain deletion mutagenesis revealing SOCS box requirement, functional readout in cell proliferation assay, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"15695332\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Socs5-deficient mice generated by targeted gene disruption show no abnormalities in lymphocyte compartment, no deviations in antigen- or cytokine-induced B and T cell proliferation, and no defects in Th1/Th2 differentiation or resistance to Leishmania major infection, indicating SOCS5 is dispensable for regulation of lymphocyte function under these conditions.\",\n      \"method\": \"Targeted gene disruption (knockout mouse), lymphocyte proliferation assays, Th1/Th2 differentiation assays, Leishmania infection model\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic KO with multiple defined cellular phenotype readouts; contradicts PMID 12242343 on Th1/Th2 role but is a rigorous null finding\",\n      \"pmids\": [\"15199163\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"SOCS5 contains a conserved JAK interaction region (JIR) in its N-terminus that mediates direct binding to the JAK kinase domain; co-expression of SOCS5 specifically reduces JAK1 and JAK2 (but not JAK3 or TYK2) autophosphorylation via a mechanism requiring both the JIR and additional N-terminal sequences; SOCS5 can directly inhibit JAK1 kinase activity through a mechanism distinct from SOCS1/SOCS3; additionally, the SOCS5 SH2 domain binds phosphoTyr317 of the adaptor protein Shc-1 with high affinity.\",\n      \"method\": \"Co-expression autophosphorylation assays, in vitro kinase assays, domain deletion and mutagenesis, SH2 domain binding assays\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro kinase activity assay, domain mutagenesis, SH2 binding assay identifying Shc-1 pY317 as substrate; multiple orthogonal methods in single lab\",\n      \"pmids\": [\"23990909\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"NMR structural characterization of the JAK interaction region (JIR) within the intrinsically disordered N-terminus of SOCS5 reveals preformed structural elements including an α-helix (residues 224–233) preceded by a turn and extended structure; a phosphorylation site (Ser211) within the JIR was identified and site-directed mutagenesis showed phosphorylation modulates JAK binding.\",\n      \"method\": \"NMR (chemical shift analysis, relaxation measurements, NOE analysis), site-directed mutagenesis\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR structural characterization with functional validation via mutagenesis; single lab but multiple orthogonal NMR methods plus mutagenesis\",\n      \"pmids\": [\"26173083\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"SOCS5 restricts influenza A virus replication in airway epithelium through regulation of EGFR signaling; Socs5-deficient mice exhibit heightened disease severity with increased viral titres; restoration of SOCS5 levels in primary COPD epithelial cells (which have reduced SOCS5) restricted influenza infection.\",\n      \"method\": \"Socs5 knockout mice, viral titration, restoration experiments in primary epithelial cells, weight loss measurements\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO mouse with defined phenotypic readout (viral titres, weight loss), plus restoration experiment in primary cells; multiple orthogonal approaches in one study\",\n      \"pmids\": [\"28195529\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In CLL patients, elevated SOCS5 (induced via IL-10-driven STAT3 activation) inhibits STAT6 activation downstream of IL-4Rα, thereby impairing differentiation of functionally mature dendritic cells; IL-10 treatment of healthy donor monocytes mimics this effect through STAT3-dependent SOCS5 upregulation.\",\n      \"method\": \"Western blot for signaling molecules, monocyte-derived DC differentiation assay, IL-10 treatment, flow cytometry for DC surface markers and cytokine secretion\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined signaling pathway placement using patient-derived cells and pharmacological mimicry; single lab, two complementary approaches\",\n      \"pmids\": [\"27317770\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"MeCP2 promotes expression of miR-124, which represses translation of SOCS5 mRNA; loss of MeCP2 leads to SOCS5 accumulation, which in turn inhibits cytokine-dependent activation of STAT1 and STAT3, impairing Th1 and Th17 cell differentiation.\",\n      \"method\": \"MeCP2 knockdown/knockout in CD4+ T cells, miR-124 expression analysis, Western blot for SOCS5 and phospho-STAT1/STAT3, Th1/Th17 differentiation assays\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic loss-of-function with defined mechanistic pathway (MeCP2→miR-124→SOCS5→STAT signaling), single lab, multiple orthogonal readouts\",\n      \"pmids\": [\"24619648\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"JEV infection downregulates miR-432 in human brain microglial cells, causing upregulation of SOCS5; elevated SOCS5 suppresses STAT1 phosphorylation and ISRE activity, thereby dampening antiviral JAK-STAT signaling and promoting JEV replication; SOCS5 knockdown restored STAT1 phosphorylation and suppressed viral replication.\",\n      \"method\": \"3'UTR luciferase reporter assay validating miR-432 targeting of SOCS5, miR-432 mimic/SOCS5 siRNA knockdown, Western blot for phospho-STAT1, ISRE reporter assay, viral replication assay\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — luciferase reporter confirming direct targeting, functional rescue experiments with defined signaling readouts; single lab\",\n      \"pmids\": [\"27282499\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SOCS5 promotes HCC cell migration and invasion by inactivating PI3K/Akt/mTOR-mediated autophagy; dual inhibition of SOCS5 and mTOR further enhances autophagy and anti-metastatic effects; stable knockdown of SOCS5 reduces HCC cell metastasis in vivo.\",\n      \"method\": \"SOCS5 siRNA knockdown and overexpression, PI3K/Akt/mTOR pathway Western blot, autophagy assays, in vitro migration/invasion assays, in vivo metastasis model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss- and gain-of-function with defined pathway readouts, in vivo validation; single lab\",\n      \"pmids\": [\"31406106\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"SOCS5 acts as a tumor suppressor in liver cancer by regulating TSC1 and downstream mTOR signaling; miR-18a and miR-25 directly target SOCS5 to promote HCC tumorigenesis.\",\n      \"method\": \"miRNA target validation (luciferase reporter), SOCS5 overexpression/knockdown in HCC cell lines, Western blot for TSC1 and mTOR pathway components, cell proliferation assays\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — luciferase reporter confirming direct miRNA targeting of SOCS5, pathway analysis via Western blot; single lab, multiple assays\",\n      \"pmids\": [\"30191950\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SOCS5 expression in T-ALL is epigenetically silenced by DNMT3A-mediated DNA methylation and MeCP2-mediated histone deacetylation; SOCS5 silencing activates JAK-STAT signaling and accelerates T-ALL engraftment and leukemia progression in a xenograft model; SOCS5 negatively regulates IL-7 and IL-4 receptor signaling in T-ALL cells.\",\n      \"method\": \"DNMT3A/MeCP2 inhibition, SOCS5 overexpression/knockdown, Western blot for JAK-STAT pathway, cell cycle analysis, human T-ALL murine xenograft model\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epigenetic mechanism identified with pharmacological and genetic approaches, in vivo xenograft validation; single lab\",\n      \"pmids\": [\"30974024\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SOCS5 interacts with RBMX via its SH2 domain (critical residues Y413 and D443 binding the RBMX RRM domain); the SOCS5-RBMX complex co-stimulates the SREBP1 promoter to induce de novo lipogenesis, promoting HCC metastasis; SH2 domain mutations Y413 and D443 abolish RBMX binding and reverse lipogenesis induction.\",\n      \"method\": \"Co-IP and GST-pulldown identifying SOCS5-RBMX interaction, SH2 domain point mutagenesis (Y413, D443), SREBP1 promoter assay, proteomics, metabolomics, in vitro and in vivo experiments\",\n      \"journal\": \"NPJ precision oncology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — reciprocal Co-IP and GST-pulldown, mutagenesis identifying critical binding residues, functional promoter assay and metabolomics; multiple orthogonal methods in single study\",\n      \"pmids\": [\"38429411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"PMA treatment of rat brain astrocytes induces SOCS5 protein expression via activation of Stat3 (tyrosine-phosphorylated Stat3 binds SOCS promoter elements), identifying Stat3-driven transcriptional induction as a mechanism for SOCS5 upregulation.\",\n      \"method\": \"Western blot for SOCS5 protein, phospho-Stat3 detection, gel-shift (EMSA) assay showing Stat3 binding to SOCS promoter elements\",\n      \"journal\": \"Molecules and cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Weak — EMSA showing nuclear Stat3 binding to SOCS promoter elements, Western blot for SOCS5 induction; single lab, limited mechanistic dissection of SOCS5 specifically\",\n      \"pmids\": [\"17464217\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SOCS5 knockdown inhibits HCC cell invasion and migration by suppressing HIF-1α expression, preventing HIF-1α-dependent mitochondrial damage; this effect operates through the PI3K/Akt/mTOR/HIF-1α signaling axis as confirmed by rescue experiments with PI3K and mTOR inhibitors.\",\n      \"method\": \"SOCS5 siRNA knockdown, CoCl2 hypoxia model, immunofluorescence, electron microscopy, PI3K/mTOR inhibitor rescue experiments, in vivo metastasis and xenograft models\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological rescue with pathway inhibitors placing SOCS5 upstream of PI3K/Akt/mTOR/HIF-1α; single lab, multiple orthogonal assays\",\n      \"pmids\": [\"36319626\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SOCS5 contributes to TMZ resistance in glioblastoma by enhancing Bcl-2 transcription, which promotes autophagy; knockdown of SOCS5 inhibits TMZ chemoresistance through inhibition of Bcl-2-mediated autophagy, and upregulation of Bcl-2 reverses this effect.\",\n      \"method\": \"SOCS5 knockdown/overexpression, Western blot for Bcl-2, autophagy assays, TMZ resistance assays, rescue experiments with Bcl-2 overexpression\",\n      \"journal\": \"Bioengineered\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — mechanistic claim (SOCS5 enhances Bcl-2 transcription) based on Western blot and rescue experiments in single lab without direct transcription assay for SOCS5 on Bcl-2 promoter\",\n      \"pmids\": [\"35730472\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"POU2F1 acts as an upstream transcriptional activator of SOCS5, and elevated SOCS5 promotes diabetic retinopathy progression by upregulating CDKN1A (p21), driving cell cycle arrest and cellular senescence; SOCS5 knockdown mitigated retinal tissue damage, vascular leakage, and DNA damage in DR models.\",\n      \"method\": \"siRNA silencing of POU2F1 and SOCS5, Western blot for CDKN1A, in vitro (HG-induced HRMECs) and in vivo (STZ-induced DR mouse) models, apoptosis and senescence assays\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — pathway placement via siRNA knockdown and Western blot; single lab, no direct transcriptional binding assay for POU2F1 on SOCS5 promoter reported in abstract\",\n      \"pmids\": [\"41922309\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CIS6/SOCS5 was cloned as a human homologue with structural features (SH2 domain and SOCS box) consistent with the SOCS family of negative regulators of JAK signaling; its gene was mapped to human chromosome bands 2p21 and 3p22.\",\n      \"method\": \"cDNA cloning, Northern blot for tissue expression, fluorescence in situ hybridization for chromosomal mapping\",\n      \"journal\": \"Cytogenetics and cell genetics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — cloning and chromosomal mapping; function inferred from structural homology, no direct functional assay\",\n      \"pmids\": [\"10773671\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SOCS5 is an intracellular suppressor of cytokine and growth factor signaling that operates through at least two distinct mechanisms: (1) its conserved N-terminal JAK interaction region (JIR) directly binds and inhibits JAK1 and JAK2 kinase activity, while its SH2 domain engages phosphoTyr317 of Shc-1 to dampen EGF/growth factor signaling; (2) it binds the IL-4Rα cytoplasmic domain independently of receptor phosphorylation to block STAT6 activation; its SOCS box recruits E3 ubiquitin ligase activity to promote proteasomal degradation of the EGF receptor; and it interacts via its SH2 domain (residues Y413/D443) with the RBMX RRM domain to co-activate SREBP1-driven lipogenesis in HCC; SOCS5 expression is itself regulated by STAT3-driven transcription, miR-124-mediated translational repression, and DNMT3A/MeCP2-mediated epigenetic silencing, placing it as a feedback node in the JAK-STAT pathway with additional roles in EGFR, PI3K/Akt/mTOR, and HIF-1α signaling.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"SOCS5 is an intracellular negative regulator of cytokine and growth-factor signaling that acts on the JAK-STAT and EGFR pathways through multiple, structurally distinct interaction modules [#3, #1]. Its conserved N-terminal JAK interaction region (JIR), an intrinsically disordered segment containing a preformed \\u03b1-helix (residues 224\\u2013233) whose JAK binding is modulated by Ser211 phosphorylation, directly binds the JAK kinase domain and selectively suppresses JAK1 and JAK2 (but not JAK3 or TYK2) autophosphorylation by a mechanism distinct from SOCS1/SOCS3; its SH2 domain additionally engages phosphoTyr317 of the adaptor Shc-1 [#3, #4]. SOCS5 also binds the IL-4R\\u03b1 cytoplasmic tail independently of receptor phosphorylation, displacing JAK1 from the receptor and inhibiting IL-4-driven STAT6 activation [#0], and associates with the EGF receptor complex EGF-independently to inhibit mitogenic signaling, an effect that requires the SOCS box and is consistent with SOCS box-mediated recruitment of E3 ubiquitin ligase activity promoting EGFR degradation [#1]. Through this control of EGFR signaling SOCS5 restricts influenza A virus replication in airway epithelium, where its loss heightens disease severity and viral titres [#5]. SOCS5 is positioned as an inducible feedback node: it is transcriptionally upregulated by tyrosine-phosphorylated STAT3 binding SOCS promoter elements [#13, #6], translationally repressed by miR-124 (downstream of MeCP2) and other miRNAs [#7], and epigenetically silenced by DNMT3A/MeCP2 in T-ALL, where silencing reactivates JAK-STAT signaling and accelerates leukemia progression [#11]. In hepatocellular carcinoma SOCS5 acquires oncogenic, signaling-independent functions: its SH2 domain (critical residues Y413/D443) binds the RBMX RRM domain, and the SOCS5-RBMX complex co-activates the SREBP1 promoter to drive de novo lipogenesis and metastasis [#12], while SOCS5 also promotes HCC migration and invasion via PI3K/Akt/mTOR-mediated autophagy and a downstream HIF-1\\u03b1 axis [#9, #14]. A Socs5 knockout shows the protein is dispensable for lymphocyte development and Th1/Th2 differentiation under standard conditions [#2].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Established SOCS5 as a candidate negative regulator of JAK signaling by cloning it and recognizing the SH2-domain/SOCS-box architecture that defines the SOCS family.\",\n      \"evidence\": \"cDNA cloning, Northern blot, and FISH chromosomal mapping\",\n      \"pmids\": [\"10773671\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Function inferred from structural homology with no direct functional assay\", \"No binding partner or substrate identified\", \"Dual chromosomal mapping (2p21 and 3p22) unresolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Provided the first mechanism, showing SOCS5 binds the IL-4R\\u03b1 cytoplasmic tail independent of receptor phosphorylation to displace JAK1 and block STAT6, dampening Th2 differentiation.\",\n      \"evidence\": \"Co-IP, transgenic mouse overexpression, and Th2 differentiation assays\",\n      \"pmids\": [\"12242343\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Phosphorylation-independent binding interface on IL-4R\\u03b1 not mapped\", \"Th2 role contradicted by later knockout data\", \"Did not establish whether endogenous SOCS5 levels recapitulate the overexpression phenotype\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Tested SOCS5 necessity genetically and found it dispensable for lymphocyte function and Th1/Th2 differentiation, narrowing where SOCS5 is physiologically required.\",\n      \"evidence\": \"Targeted gene-disruption knockout mouse with lymphocyte proliferation, Th1/Th2, and Leishmania infection readouts\",\n      \"pmids\": [\"15199163\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Possible redundancy with other SOCS proteins not excluded\", \"Conditions tested may not engage SOCS5-dependent contexts\", \"Conflicts with the overexpression-based Th2 phenotype\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Extended SOCS5 action to growth-factor signaling by showing EGF-independent association with the EGFR complex and SOCS-box-dependent inhibition of mitogenic signaling.\",\n      \"evidence\": \"Co-IP, SOCS-box deletion mutants, and proliferation assays in engineered EGF-responsive lines\",\n      \"pmids\": [\"15695332\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ligase recruitment and EGFR ubiquitination inferred but not directly demonstrated\", \"Specific EGFR residues or adaptor mediating binding not defined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Defined the direct enzymatic mechanism, identifying the N-terminal JIR that binds the JAK kinase domain and selectively inhibits JAK1/JAK2 activity, plus an SH2-Shc-1 pY317 interaction.\",\n      \"evidence\": \"Co-expression autophosphorylation assays, in vitro kinase assays, domain mutagenesis, and SH2 binding assays\",\n      \"pmids\": [\"23990909\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of JAK1/JAK2 selectivity over JAK3/TYK2 unresolved\", \"Functional consequence of Shc-1 pY317 binding in cells not established\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Resolved the conformational basis of JAK recognition, showing the disordered JIR contains a preformed \\u03b1-helix and a Ser211 phosphosite that tunes JAK binding.\",\n      \"evidence\": \"NMR chemical shift, relaxation, and NOE analysis with site-directed mutagenesis\",\n      \"pmids\": [\"26173083\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinase responsible for Ser211 phosphorylation unknown\", \"No co-structure of the JIR bound to JAK\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identified an upstream input, showing PMA-induced STAT3 binds SOCS promoter elements to drive SOCS5 transcription, placing SOCS5 in a feedback loop.\",\n      \"evidence\": \"Western blot for SOCS5, phospho-Stat3 detection, and EMSA in rat astrocytes\",\n      \"pmids\": [\"17464217\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"EMSA used generic SOCS promoter elements rather than dissecting the SOCS5 promoter specifically\", \"Direct STAT3 occupancy of the SOCS5 locus not shown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Established post-transcriptional and epigenetic control, showing the MeCP2\\u2192miR-124 axis represses SOCS5 translation, with SOCS5 accumulation inhibiting STAT1/STAT3 and Th1/Th17 differentiation.\",\n      \"evidence\": \"MeCP2 knockdown/knockout in CD4+ T cells, miR-124 analysis, and Th1/Th17 differentiation assays\",\n      \"pmids\": [\"24619648\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct miR-124 binding to the SOCS5 3'UTR not separately validated here\", \"Mechanism of SOCS5-mediated STAT1/STAT3 inhibition in this context not dissected\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Linked SOCS5 regulation to immune dysfunction, showing IL-10/STAT3-driven SOCS5 upregulation blocks STAT6 and impairs dendritic cell maturation in CLL, and miR-432 loss raises SOCS5 to suppress STAT1 antiviral signaling during JEV infection.\",\n      \"evidence\": \"Patient-derived cells with IL-10 mimicry and DC differentiation assays (CLL); 3'UTR luciferase reporter, siRNA rescue, and ISRE/viral replication assays (JEV)\",\n      \"pmids\": [\"27317770\", \"27282499\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether SOCS5-mediated STAT inhibition uses JAK displacement or kinase inhibition in these settings not resolved\", \"Direct SOCS5 occupancy of receptors in patient cells not shown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Demonstrated a physiological antiviral role, showing SOCS5 restricts influenza A in airway epithelium via EGFR regulation, with loss worsening disease and restoration protecting COPD epithelium.\",\n      \"evidence\": \"Socs5 knockout mice, viral titration, weight loss, and restoration in primary epithelial cells\",\n      \"pmids\": [\"28195529\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular link between SOCS5-EGFR control and viral restriction not fully detailed\", \"Relevance of JAK-inhibitory function to this phenotype not separated from EGFR function\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Assigned SOCS5 a tumor-suppressor role in liver cancer through TSC1/mTOR regulation, with miR-18a and miR-25 directly targeting SOCS5 to drive HCC.\",\n      \"evidence\": \"miRNA luciferase target validation, SOCS5 gain/loss-of-function, and TSC1/mTOR Western blots\",\n      \"pmids\": [\"30191950\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Conflicts with reports of oncogenic SOCS5 function in HCC\", \"Mechanistic link between SOCS5 and TSC1 not biochemically defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Revealed context-dependent oncogenic activity, showing SOCS5 promotes HCC migration/invasion via PI3K/Akt/mTOR-mediated autophagy, and that DNMT3A/MeCP2-driven SOCS5 silencing accelerates T-ALL by reactivating JAK-STAT.\",\n      \"evidence\": \"SOCS5 knockdown/overexpression with pathway Western blots and in vivo metastasis (HCC); epigenetic inhibition and xenograft (T-ALL)\",\n      \"pmids\": [\"31406106\", \"30974024\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Opposing tumor-suppressor vs oncogenic roles of SOCS5 in HCC unreconciled\", \"Direct molecular target linking SOCS5 to PI3K/Akt/mTOR not identified\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Expanded the HCC oncogenic mechanism through a HIF-1\\u03b1 axis and proposed a glioblastoma chemoresistance role via Bcl-2-mediated autophagy.\",\n      \"evidence\": \"SOCS5 knockdown with PI3K/mTOR inhibitor rescue and metastasis models (HCC); SOCS5 knockdown/overexpression with Bcl-2 rescue (GBM)\",\n      \"pmids\": [\"36319626\", \"35730472\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Bcl-2 transcriptional enhancement by SOCS5 lacks a direct promoter assay\", \"How a SOCS-family signaling inhibitor mechanistically activates oncogenic axes remains undefined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defined a non-canonical SOCS5 function, showing its SH2 domain (Y413/D443) binds the RBMX RRM domain and the complex co-activates the SREBP1 promoter to drive lipogenesis and HCC metastasis.\",\n      \"evidence\": \"Co-IP, GST-pulldown, SH2 point mutagenesis, SREBP1 promoter assay, proteomics, and metabolomics\",\n      \"pmids\": [\"38429411\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How the SOCS5-RBMX complex engages the SREBP1 promoter mechanistically not resolved\", \"Relationship of this nuclear/lipogenic role to SOCS5's cytoplasmic signaling-inhibitory functions unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How SOCS5 switches between its canonical signaling-suppressor role (JAK inhibition, IL-4R\\u03b1/EGFR regulation) and its context-dependent oncogenic functions (RBMX/SREBP1 lipogenesis, PI3K/mTOR/HIF-1\\u03b1) remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of full-length SOCS5 bound to JAK or EGFR\", \"E3 ligase identity and direct ubiquitination substrates not confirmed\", \"Opposing tumor-suppressor and oncogenic roles, especially in HCC, not reconciled\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1, 3]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [3, 12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 1, 3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 3]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 5, 11]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"IL4R\", \"EGFR\", \"JAK1\", \"JAK2\", \"SHC1\", \"RBMX\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}